Clinigen Share Discussion Threads

[cornishman33] 07/10/2013 16:18

Quite a lot of negative comments on here last week after the placing was announced and some director selling. I decided to hang on and today the price has rocketed on a poor day. Is there something in the offing?

[cestnous] 07/10/2013 09:23

New highs. Seems my fears were unfounded; hopefully.

[aishah] 02/10/2013 10:59

Clinigen Group plc ("Clinigen" or the "Company", AIM: CLIN), announces that it was informed on 1 October 2013 that, following yesterday morning's placing, as a result of additional late US institutional demand, on 1 October 2013, Peter George, Chief Executive Officer of the Company, sold a further 500,000 ordinary shares of 0.1p each in the Company at a price of 410p per share.

[aishah] 01/10/2013 14:05

I don't begrudge them cashing in. They've done very well for shareholders post floatation (Doubler for me). Nice to have new investors on board. Numis has 485p target.

[phowdo] 01/10/2013 13:40

What rankles is it has (presumably) been done so close to a one year lockin period lapsing. It reminds me of that famous psychology experiment that shows kids who can defer taking rewards go on to become more successful than their peers who cant...

Ive taken profits here so Im being a bit hypocritical.


Edit: Im pretty impressed they got them all away at 410p. There must be good demand still

[rampmeister] 01/10/2013 13:10

They are cashing in on the high share price after a good run imv. I am holding from 219P so no complaints. Market seems to have given it the thumbs up after cautious start. RNS to follow soon.

RM

[cestnous] 01/10/2013 10:58

But why do it? If it's for liquidity, why not say so? If it's to grab some cash as the board sees this as a top for a while, the share price will stagnate. Still holding but not with the same confidence.

[kenmill1] 01/10/2013 09:20

I agree - a short term dampener but better done this way than dribbled out on the market over a period.

[aishah] 01/10/2013 08:28

I reckon there'll be good demand for these given their outlook and prospects. dyor

[cestnous] 01/10/2013 08:16

Does not look good. Not even a reason given and announced after the market closed. Very disappointing but not totally unexpected on Aim.

[nermil] 30/9/2013 17:54

For the being I'm glad I sold on Friday. I don't see how this can be positive in the short run although the business model still stacks up.

[rjd1233] 30/9/2013 16:55

Clinigen Group plc

30 September 2013

PROPOSED SECONDARY PLACING OF ORDINARY SHARES IN CLINIGEN GROUP PLC

Burton-on-Trent, UK - 30 September 2013 - Clinigen Group plc ("Clinigen" or the "Company", AIM: CLIN), the global specialty pharmaceuticals and services company, today announces that it has been advised by Numis Securities Limited ("Numis") acting as bookrunner and joint broker and Peel Hunt LLP ("Peel Hunt") acting as joint broker that, as instructed by several Directors and employees of Clinigen set out below ("the Vendors"), Numis and Peel Hunt intend to sell up to 8,723,826 existing ordinary shares of 0.1p each in the Company ("the Placing Shares") on behalf of the Vendors via an accelerated bookbuild placing ("the Placing"). The Placing Shares represent in aggregate approximately 10.6 per cent of the 82,555,585 ordinary shares which comprise the issued share capital of Clinigen.

Details of the maximum numbers of Placing Shares to be disposed of by the Vendors are as follows:



Resultant shareholding Proportion
assuming all Placing of current
Shares are sold shareholding
sold assuming
all Placing
Shares are
sold
------------------- ------------ ------------------------- --------------
Director/employee Maximum Shares %
number
of Placing
Shares
------------------- ------------ ---------------- ------- --------------
Peter George 2,832,500 6,057,242 7.3 31.9%
------------------- ------------ ---------------- ------- --------------
Robin Sibson 2,480,516 2,480,516 3.0 50.0%
------------------- ------------ ---------------- ------- --------------
Shaun Chilton 303,800 303,800 0.4 50.0%
------------------- ------------ ---------------- ------- --------------
Other employees 3,107,010 3,118,922 3.8 49.9%
------------------- ------------ ---------------- ------- --------------
Total 8,723,826 11,960,480 14.5
------------------- ------------ ---------------- ------- --------------

The Placing will be managed by Numis acting as bookrunner (the "Bookrunner") with Peel Hunt acting as joint broker. The number of Placing Shares and the Placing price will be decided at the close of the accelerated bookbuilding period.

The books for the Placing will open with immediate effect. Pricing is expected to be announced as soon as practicable following the closing of the books. The timing of closing of the books will be at the absolute discretion of the Bookrunner in consultation with Peel Hunt.

[malhashemi] 30/9/2013 16:55

Sold out of this back when it was 275p and been waiting to get back in. Just saw the RNS that the directors are selling 10% of their shares in the company .. Not sure if that's a good sign to sell out at such a scale, but I guess they want to lock in profits given the run in shares... Will keep an eye on these

[cestnous] 28/9/2013 14:29

I don't buy any of those. :¬)

[gbb483] 27/9/2013 18:00

I wonder if IC are as open about their tips that bomb?

[cestnous] 27/9/2013 09:33

I.C.TIP UPDATE
Clinigen Group PLC (CLIN)
GROWTH
MEDIUM RISK

Our previous tip
WE SAIDBuy
WHEN18 Jan 2013
PRICE220p
TIP PERFORMANCE TO DATE+100%
Medical services supplier Clinigen (CLIN) produced a very strong set of maiden full-year results following its market listing late last year. These were all the more impressive because the 29 per cent growth in underlying pre-tax profits was generated almost entirely organically. That suggests that its unusual strategy of supplying products to global clinical trials, and giving a new sales life to moribund medicines acquired from big pharma companies, is starting to reap real rewards.

Clinigen's main niche is the supply of so-called comparator drugs to clinical trials around the world. Sales at the CTS segment jumped by 49 per cent to £87.8m, as Clinigen significantly broadened its customer base from 52 to 72 during the year. However, the standout performance came from the global access business, which specialises in product consultancy. Sales here surged more than sixfold to £10.5m, with gross profits rising from £0.7m to £3.9m. Meanwhile, the addition of a bone marrow indication to Foscavir, in addition to conditions associated with HIV infection, boosted sales of the product by 12 per cent to £24.3m, including 3.9 per cent like-for-like growth between the first and second halves.

Chief executive Peter George said that Clinigen will benefit this year from the contribution of newly acquired toxicity treatment Cardioxane, and antibiotic Vibativ.

Broker Peel Hunt forecasts pre-tax profits of £26.1m and EPS of 23.6p, compared with £20.4m and 20.1p in 2013.

CLINIGEN (CLIN)
ORD PRICE: 435p MARKET VALUE: £359m
TOUCH: 430-440p 12-MONTH HIGH: 440p LOW: 168p
DIVIDEND YIELD: 0.6% PE RATIO: 29
NET ASSET VALUE: 62p* NET CASH: £11.3m
Year to 30 Jun Turnover (£m) Pre-tax profit (£m) Earnings per share (p) Dividend per share (p)
2010 21 1.2 na nil
2011 35 6.8 na nil
2012 82 10.2 13.2 nil
2013 123 14.5 15.1 2.6
% change +50 +42 +14 -
Ex-div: 9 Oct

Payment: 1 Nov

*Includes intangible assets of £38.9m, or 47p a share

TIP UPDATE:
Clinigen's share price has doubled on our buy tip (220p, 18 Jan 2013), but rated on 16 times June 2015 earnings estimates there should be more upside to come, as earnings ramp up on the back of new products. Buy.

Last IC view: Buy, 340p, 1 Aug 201

[rampmeister] 25/9/2013 16:24

With Clinigen GAP revenue growing more than six-fold and new products coming on stream see no reason why good momentum can not be maintained. Forecasts for 2014 of eps +17% are there to be broken imv.

RM

[ceohunter] 25/9/2013 14:15

video interview
Clinigen says momentum has carried into the new financial year

Clinigen chief executive Peter George (LON:CLIN) reveals all three of the group's businesses posted "good organic growth" in the last 12 months, with momentum carrying over into the new financial year. He added Clinigen had "really enjoyed the experience" of its first year as a listed company -- one in which the shares have more than doubled in value.

[ygor706] 25/9/2013 13:36

The Directors will soon be outside the 1 year moratorium period for selling shares and I suspect that they may want to cash in at least some of their holding. The results are good but no better than consensus and I'm slightly surprised by the market's reaction. Still, it's good to see a bit of blue on the Board!

[cestnous] 25/9/2013 12:01

Yes, looks like we've brken well above the 400p mark at last.

[leeson31] 25/9/2013 09:41

nice rise here!

[aishah] 25/9/2013 09:39

Numis, Buy, 485p target

[apad] 25/9/2013 07:25

Headlines look good.
Trying to get to grips with the cash flow statement - I hate it when they start from operating profit and then add thing back.
Anyone know a good rough guide to reading cash flow statements?
apad

[ygor706] 25/9/2013 07:20

Eps is spot on Broker's consensus; dps is ahead of expectations. Where we go from here is down to the market's view of next year's prospects.